A5080786563- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Urinary Bladder and Prostate Research
- Erythrocyte Function and Pathophysiology
- Gut microbiota and health
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Pneumonia and Respiratory Infections
- Immune cells in cancer
- COVID-19 Clinical Research Studies
- Mycobacterium research and diagnosis
- Tuberculosis Research and Epidemiology
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Antibiotic Use and Resistance
- Acute Lymphoblastic Leukemia research
- Lung Cancer Research Studies
- Urinary Tract Infections Management
Johns Hopkins Medicine
2024-2025
Johns Hopkins University
2024-2025
Sidney Kimmel Comprehensive Cancer Center
2024
American University of Beirut Medical Center
2023
American University of Beirut
2022
Patients with myeloid neoplasms loss-of-function TP53 mutations and erythroid differentiation have poor outcomes, a better understanding of disease biology is required. Upregulation interferon-γ (IFN-γ) signaling has been associated acute leukemia (AML) progression chemotherapy resistance, but its drivers remain unclear. In this study, we found that the surface receptor C-C motif chemokine receptor-like 2 (CCRL2) overexpressed in AML compared to other subtypes healthy hematopoietic cells....
Tuberculosis (TB) remains among the leading infectious causes of death. Due to limited number antimicrobials in TB drug discovery pipeline, interest has developed host-directed approaches improve treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) is a unique seven-transmembrane domain that upregulated by inflammatory signals and mediates leucocyte migration. However, little known about its role infection. Here, we show Mycobacterium tuberculosis (Mtb) infection increases CCRL2...
Many healthcare centers around the world have reported surge of Candida auris (C. auris) outbreaks during COVID-19 pandemic, especially among intensive care unit (ICU) patients. This is a retrospective study conducted at American University Beirut Medical Center (AUBMC) between 1 October 2020 and 15 June 2021, to identify risk factors for acquiring C. in patients with severe infection evaluate impact on mortality admitted ICU that period. Twenty-four non-COVID-19 (COV−) were ICUs AUBMC...
Acute Erythroid Leukemia (AEL) is a rare and aggressive subtype of Myeloid (AML). In 2022, the World Health Organization (WHO) defined AEL as biopsy with ≥30% proerythroblasts erythroid precursors that account for ≥80% cellularity. The International Consensus Classification refers to this neoplasm “AML mutated TP53”. entails ≥20% blasts in blood or bone marrow somatic TP53 mutation (VAF > 10%). This type leukemia typically associated biallelic mutations complex karyotype, specifically 5q...
Lung cancer is the number one cause of mortality among all types worldwide. Its treatment landscape has shifted from classic chemotherapy alone to newer regimens based on discovery new immunotherapy and targeted therapy drugs. However, still an option for advanced non-small cell lung (NSCLC) after progression or in combination with first-line chemotherapy.This a retrospective study chart review patients diagnosed NSCLC cases who received Docetaxel as second third line being treated by and/or...
Tuberculosis (TB) remains among the leading infectious causes of death. Due to limited number antimicrobials in TB drug discovery pipeline, interest has developed host-directed approaches improve treatment outcomes. C-C motif chemokine-like receptor 2 (CCRL2) is a unique seven-transmembrane domain that upregulated by inflammatory signals and mediates leucocyte migration. However, little known about its role setting infection. Here, we show